Abstract
Learning Objectives:
Review the pathophysiology and characteristics of breakthrough cancer pain, its prevalence and its distinction from baseline pain.
Discuss the current management of breakthrough cancer pain in Canada, its strengths and its limitations.
List attributes of a new class of drugs - rapid onset opioids - and outline how they are used in clinical practice.
BRIEF DESCRIPTION:
Breakthrough cancer pain is phenomenologically distinct from persistent chronic cancer pain, and requires different management strategies. While baseline cancer pain is typically fairly steady, breakthrough cancer pain is commonly sudden in onset, typically reaching peak intensity after about 3 minutes. Episodes of breakthrough cancer pain can be predictable, but in approximately 80% of patients, breakthrough pain occurs unpredictably. (1) Physicians treating cancer patients need to undertake a proper assessment of pain in order to ensure appropriate pain management. Results from one survey suggested that only 25% of patients with breakthrough pain are satisfied with pain control compared to 78% of patients without breakthrough pain. (1) Difficulties in identifying breakthrough pain, and the availability of new emerging therapy justify the need for attention to gaps in current diagnosis and treatment, and implementation of measures to reduce these gaps.
REFERENCES
- 1.Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81(1–2):129–134. doi: 10.1016/s0304-3959(99)00006-8. [DOI] [PubMed] [Google Scholar]
